<p>Sawyer &amp; Company Inc 在第一季度減持了 Amgen Inc.（納斯達克股票代碼：AMGN - 免費報告）的持股比例，根據最近向證券交易委員會提交的文件。該公司在此期間賣出了 29,752 股，持有這家醫療研究公司的股票 15,853 股。在 Sawyer &amp; Company Inc 的投資組合中，Amgen 佔比 1.8%，是其第 17 大持倉。截至最近一個季度末，Sawyer &amp; Company Inc 對 Amgen 的持股價值為 4,507,000 美元。</p>
<ul>
<li>Moderna 股價飆升，因推出尖端個性化癌症疫苗</li>
</ul>
<p>其他幾家機構投資者和對沖基金最近也對該公司的持股進行了調整。Diversified Trust Co 在第四季度將其在 Amgen 的持股比例提高了 76.8%。Diversified Trust Co 現在擁有 37,695 股 Amgen 的股票，價值 10,857,000 美元，比之前增持了 16,376 股。Provence Wealth Management Group 在第四季度將其在 Amgen 的持股比例提高了 11.9%。Provence Wealth Management Group 現在擁有 1,445 股 Amgen 的股票，價值 416,000 美元，比之前增持了 154 股。Kinsale Capital Group Inc.在第四季度將其在 Amgen 的持股比例提高了 33.0%。Kinsale Capital Group Inc.現在擁有 11,348 股 Amgen 的股票，價值 3,269,000 美元，比之前增持了 2,814 股。Global Wealth Management Investment Advisory Inc.在第四季度將其在 Amgen 的持股比例提高了 2.4%。Global Wealth Management Investment Advisory Inc.現在擁有 4,733 股 Amgen 的股票，價值 1,363,000 美元，比之前增持了 109 股。最後，Traynor Capital Management Inc.在第四季度將其在 Amgen 的持股比例提高了 9.5%。Traynor Capital Management Inc.現在擁有 18,941 股 Amgen 的股票，價值 5,455,000 美元，比之前增持了 1,650 股。機構投資者和對沖基金擁有公司股份的 76.50%。</p>
<h2>分析師評級變動</h2>
<p>一些股票分析師最近對該股發表了意見。TD Cowen 將 Amgen 的目標股價從 370.00 美元降至 360.00 美元，並在 4 月 17 日星期三的研究報告中為該公司設定了 “買入” 評級。Truist Financial 在 4 月 12 日星期五的研究報告中重申了對 Amgen 的 “買入” 評級，並設定了 320.00 美元的價格目標。StockNews.com 在 5 月 3 日星期五的研究報告中，將 Amgen 的股票評級從 “持有” 調升至 “買入”。巴克萊在 5 月 3 日星期五的研究報告中，將 Amgen 的股票評級從 “輕倉” 調升至 “等權”，並將股票的價格目標從 230.00 美元提高至 300.00 美元。最後，阿格斯在週四的研究報告中，將 Amgen 的股票價格目標從 300.00 美元提高至 340.00 美元，並給予該股票 “買入” 評級。十位投資分析師對該股進行了持有評級，十二位分析師對該股進行了買入評級。根據 MarketBeat 的數據，Amgen 的平均評級為 “中性買入”，平均目標股價為 307.35 美元。</p>
<ul>
<li>生物科技行業接近突破：第二季度表現將優於市場嗎？</li>
</ul>
<p><strong>閲讀我們對 AMGN 的最新分析</strong></p>
<h2>Amgen 內部交易</h2>
<ul>
<li>7 支將推動減肥藥市場的股票</li>
</ul>
<p>另外，高級副總裁 Nancy A. Grygiel 於 5 月 3 日星期五進行了一筆交易，出售了公司股票 2,117 股。這些股票的平均價格為 313.09 美元，交易總額為 662,811.53 美元。交易完成後，這位高級副總裁現在持有公司股票 9,883 股，價值 3,094,268.47 美元。該交易已在向證券交易委員會提交的法律文件中披露，可以通過此超鏈接獲得。公司內部人士持有公司股份的比例為 0.69%。</p>
<h2>Amgen 股票表現</h2>
<ul>
<li>7 支將推動減肥藥市場的股票</li>
</ul>
<p>納斯達克 AMGN 週五開盤價為 312.45 美元。該公司的流動比率為 1.42，速動比率為 0.98，負債權益比為 11.96。該公司的市值為 167.61 億美元，市盈率為 44.64，市盈增長比率為 2.83，貝塔係數為 0.60。該公司的 50 天簡單移動平均線為 301.56 美元，200 天簡單移動平均線為 292.10 美元。Amgen Inc.的一年最低價為 218.44 美元，最高價為 329.72 美元。</p>
<p>Amgen（納斯達克股票代碼：AMGN - 獲取免費報告）於 5 月 2 日星期四發佈了其盈利結果。該醫療研究公司報告本季度每股盈利 3.96 美元，超過分析師對 3.76 美元的共識預期 0.20 美元。Amgen 的淨利潤率為 12.74%，淨資產收益率為 156.21%。本季度，該公司的營收為 74.5 億美元，略高於分析師對 74.5 億美元的預期。與去年同期相比，公司的季度營收增長了 22.0%。研究分析師預計，Amgen Inc.本財年的每股盈利將達到 19.47 美元。</p>
<h2>Amgen 公司簡介（免費報告）</h2>
<p>Amgen Inc（安進公司）在全球範圍內發現、開發、生產和提供人類治療藥物。該公司的主要產品包括用於治療斑塊性銀屑病、類風濕關節炎和銀屑病性關節炎的安達治（Enbrel）；用於治療成年患者斑塊性銀屑病、銀屑病性關節炎和貝赫切特氏病口腔潰瘍的奧特茲拉（Otezla）；用於治療絕經後婦女骨質疏鬆症的普羅利亞（Prolia）；用於預防骨相關事件的 XGEVA；降低心肌梗死、中風和冠狀動脈重建風險的瑞帕塔（Repatha）；用於治療免疫性血小板減少症患者的 Nplate；用於治療複發性或難治性多發性骨髓瘤患者的 KYPROLIS；用於治療紅細胞數量低於正常水平和貧血的阿拉內斯普（Aranesp）；用於治療絕經後男性和女性骨質疏鬆症的伊文尼蒂（EVENITY）；用於治療野生型 RAS 轉移性結直腸癌患者的維克替胞（Vectibix）；用於治療急性淋巴細胞白血病患者的布林西託（BLINCYTO）；用於治療甲狀腺眼病的泰珀扎（TEPEZZA）；以及用於治療慢性難治性痛風的克里斯特克薩（KRYSTEXXA）。</p>
<h2>推薦故事</h2>
<ul>
<li>五隻我們比安進更喜歡的股票</li>
<li>投資者如何從盤後交易中受益</li>
<li>瓦爾格林股價暴跌背後的原因：投資者下一步該怎麼做</li>
<li>道指狗策略背後的原理和示例</li>
<li>MarketBeat 周評 - 6/24 - 6/28</li>
<li>什麼是標普 500 指數及其與其他指數的區別</li>
<li>通用磨坊財報季度四營收不及預期後股價下跌</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1HTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1HTg"/></p>
<p><em>這則即時新聞警報是由 Narrative Science 技術和 MarketBeat 的財務數據生成，旨在為讀者提供最快速和最準確的報道。本故事在發佈前經過 MarketBeat 編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com。</em></p>
<p>→ 意想不到的選舉震撼…（但你會看到它的到來）（來自 Banyan Hill Publishing）（廣告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NTk4?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NTk4"/></p>
<h2>現在是否值得投資 1000 美元購買安進股票？</h2>
<p>在考慮購買安進股票之前，您應該聽聽這個消息。</p>
<p>MarketBeat 追蹤華爾街評級最高、表現最佳的研究分析師以及他們每天向客户推薦的股票。MarketBeat 已經確定了五隻頂級分析師悄悄告訴他們的客户現在購買的股票清單…而安進並不在其中。</p>
<p>雖然安進目前在分析師中有 “中等買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

安進

<p>薩耶公司在第一季度將其在安進公司的持倉減少了 65.2%。其他機構投資者和對沖基金也對該公司的持倉進行了調整。分析師對該股票的評級大多是積極的。另外，高級副總裁南希·A·格里吉爾出售了該公司股票。安進公司的股票表現一直是積極的</p>

<p>Sawyer &amp; Company Inc decreased its position in Amgen Inc. (NASDAQ:AMGN - Free Report) by 65.2% in the 1st quarter, according to its most recent filing with the Securities &amp; Exchange Commission. The firm owned 15,853 shares of the medical research company's stock after selling 29,752 shares during the period. Amgen makes up 1.8% of Sawyer &amp; Company Inc's portfolio, making the stock its 17th largest position. Sawyer &amp; Company Inc's holdings in Amgen were worth $4,507,000 at the end of the most recent quarter.</p>
<ul>
<li>Moderna Stock Soars on Cutting-Edge Personalized Cancer Vaccines</li>
</ul>
<div class="lb-trans"><p>Sawyer &amp; Company Inc 在第一季度減持了 Amgen Inc.（納斯達克股票代碼：AMGN - 免費報告）的持股比例，根據最近向證券交易委員會提交的文件。該公司在此期間賣出了 29,752 股，持有這家醫療研究公司的股票 15,853 股。在 Sawyer &amp; Company Inc 的投資組合中，Amgen 佔比 1.8%，是其第 17 大持倉。截至最近一個季度末，Sawyer &amp; Company Inc 對 Amgen 的持股價值為 4,507,000 美元。</p>
<ul>
<li>Moderna 股價飆升，因推出尖端個性化癌症疫苗</li>
</ul>
</div><p>Several other institutional investors and hedge funds also recently made changes to their positions in the company. Diversified Trust Co boosted its stake in Amgen by 76.8% in the 4th quarter. Diversified Trust Co now owns 37,695 shares of the medical research company's stock worth $10,857,000 after purchasing an additional 16,376 shares during the period. Provence Wealth Management Group boosted its stake in Amgen by 11.9% in the 4th quarter. Provence Wealth Management Group now owns 1,445 shares of the medical research company's stock worth $416,000 after purchasing an additional 154 shares during the period. Kinsale Capital Group Inc. boosted its stake in Amgen by 33.0% in the 4th quarter. Kinsale Capital Group Inc. now owns 11,348 shares of the medical research company's stock worth $3,269,000 after purchasing an additional 2,814 shares during the period. Global Wealth Management Investment Advisory Inc. boosted its stake in Amgen by 2.4% in the 4th quarter. Global Wealth Management Investment Advisory Inc. now owns 4,733 shares of the medical research company's stock worth $1,363,000 after purchasing an additional 109 shares during the period. Finally, Traynor Capital Management Inc. boosted its stake in Amgen by 9.5% in the 4th quarter. Traynor Capital Management Inc. now owns 18,941 shares of the medical research company's stock worth $5,455,000 after purchasing an additional 1,650 shares during the period. Institutional investors and hedge funds own 76.50% of the company's stock.</p>
<div class="lb-trans"><p>其他幾家機構投資者和對沖基金最近也對該公司的持股進行了調整。Diversified Trust Co 在第四季度將其在 Amgen 的持股比例提高了 76.8%。Diversified Trust Co 現在擁有 37,695 股 Amgen 的股票，價值 10,857,000 美元，比之前增持了 16,376 股。Provence Wealth Management Group 在第四季度將其在 Amgen 的持股比例提高了 11.9%。Provence Wealth Management Group 現在擁有 1,445 股 Amgen 的股票，價值 416,000 美元，比之前增持了 154 股。Kinsale Capital Group Inc.在第四季度將其在 Amgen 的持股比例提高了 33.0%。Kinsale Capital Group Inc.現在擁有 11,348 股 Amgen 的股票，價值 3,269,000 美元，比之前增持了 2,814 股。Global Wealth Management Investment Advisory Inc.在第四季度將其在 Amgen 的持股比例提高了 2.4%。Global Wealth Management Investment Advisory Inc.現在擁有 4,733 股 Amgen 的股票，價值 1,363,000 美元，比之前增持了 109 股。最後，Traynor Capital Management Inc.在第四季度將其在 Amgen 的持股比例提高了 9.5%。Traynor Capital Management Inc.現在擁有 18,941 股 Amgen 的股票，價值 5,455,000 美元，比之前增持了 1,650 股。機構投資者和對沖基金擁有公司股份的 76.50%。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析師評級變動</h2>
</div><p>A number of equities analysts recently weighed in on the stock. TD Cowen reduced their target price on shares of Amgen from $370.00 to $360.00 and set a &#34;buy&#34; rating for the company in a research note on Wednesday, April 17th. Truist Financial restated a &#34;buy&#34; rating and set a $320.00 price objective on shares of Amgen in a research note on Friday, April 12th. StockNews.com upgraded shares of Amgen from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research note on Friday, May 3rd. Barclays upgraded shares of Amgen from an &#34;underweight&#34; rating to an &#34;equal weight&#34; rating and increased their price objective for the stock from $230.00 to $300.00 in a research note on Friday, May 3rd. Finally, Argus increased their price objective on shares of Amgen from $300.00 to $340.00 and gave the stock a &#34;buy&#34; rating in a research note on Thursday. Ten investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat, Amgen has an average rating of &#34;Moderate Buy&#34; and an average price target of $307.35.</p>
<ul>
<li>Biotech Sector Nears Breakout: Will it Outperform in Q2?</li>
</ul>
<div class="lb-trans"><p>一些股票分析師最近對該股發表了意見。TD Cowen 將 Amgen 的目標股價從 370.00 美元降至 360.00 美元，並在 4 月 17 日星期三的研究報告中為該公司設定了 “買入” 評級。Truist Financial 在 4 月 12 日星期五的研究報告中重申了對 Amgen 的 “買入” 評級，並設定了 320.00 美元的價格目標。StockNews.com 在 5 月 3 日星期五的研究報告中，將 Amgen 的股票評級從 “持有” 調升至 “買入”。巴克萊在 5 月 3 日星期五的研究報告中，將 Amgen 的股票評級從 “輕倉” 調升至 “等權”，並將股票的價格目標從 230.00 美元提高至 300.00 美元。最後，阿格斯在週四的研究報告中，將 Amgen 的股票價格目標從 300.00 美元提高至 340.00 美元，並給予該股票 “買入” 評級。十位投資分析師對該股進行了持有評級，十二位分析師對該股進行了買入評級。根據 MarketBeat 的數據，Amgen 的平均評級為 “中性買入”，平均目標股價為 307.35 美元。</p>
<ul>
<li>生物科技行業接近突破：第二季度表現將優於市場嗎？</li>
</ul>
</div><p><strong>Read Our Latest Analysis on AMGN</strong></p>
<div class="lb-trans"><p><strong>閲讀我們對 AMGN 的最新分析</strong></p>
</div><h2>Insider Buying and Selling at Amgen</h2>
<div class="lb-trans"><h2>Amgen 內部交易</h2>
<ul>
<li>7 支將推動減肥藥市場的股票</li>
</ul>
</div><p>In other news, SVP Nancy A. Grygiel sold 2,117 shares of the firm's stock in a transaction on Friday, May 3rd. The shares were sold at an average price of $313.09, for a total transaction of $662,811.53. Following the completion of the transaction, the senior vice president now owns 9,883 shares of the company's stock, valued at $3,094,268.47. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available through this hyperlink. Company insiders own 0.69% of the company's stock.</p>
<div class="lb-trans"><p>另外，高級副總裁 Nancy A. Grygiel 於 5 月 3 日星期五進行了一筆交易，出售了公司股票 2,117 股。這些股票的平均價格為 313.09 美元，交易總額為 662,811.53 美元。交易完成後，這位高級副總裁現在持有公司股票 9,883 股，價值 3,094,268.47 美元。該交易已在向證券交易委員會提交的法律文件中披露，可以通過此超鏈接獲得。公司內部人士持有公司股份的比例為 0.69%。</p>
</div><h2>Amgen Stock Performance</h2>
<ul>
<li>7 Stocks That Will Drive the Weight Loss Drugs Market</li>
</ul>
<div class="lb-trans"><h2>Amgen 股票表現</h2>
<ul>
<li>7 支將推動減肥藥市場的股票</li>
</ul>
</div><p>NASDAQ AMGN opened at $312.45 on Friday. The company has a current ratio of 1.42, a quick ratio of 0.98 and a debt-to-equity ratio of 11.96. The firm has a market capitalization of $167.61 billion, a price-to-earnings ratio of 44.64, a P/E/G ratio of 2.83 and a beta of 0.60. The firm's 50 day simple moving average is $301.56 and its 200 day simple moving average is $292.10. Amgen Inc. has a 1 year low of $218.44 and a 1 year high of $329.72.</p>
<div class="lb-trans"><p>納斯達克 AMGN 週五開盤價為 312.45 美元。該公司的流動比率為 1.42，速動比率為 0.98，負債權益比為 11.96。該公司的市值為 167.61 億美元，市盈率為 44.64，市盈增長比率為 2.83，貝塔係數為 0.60。該公司的 50 天簡單移動平均線為 301.56 美元，200 天簡單移動平均線為 292.10 美元。Amgen Inc.的一年最低價為 218.44 美元，最高價為 329.72 美元。</p>
</div><p>Amgen (NASDAQ:AMGN - Get Free Report) last issued its earnings results on Thursday, May 2nd. The medical research company reported $3.96 earnings per share for the quarter, beating analysts' consensus estimates of $3.76 by $0.20. Amgen had a net margin of 12.74% and a return on equity of 156.21%. The firm had revenue of $7.45 billion for the quarter, compared to analyst estimates of $7.45 billion. During the same quarter last year, the business posted $3.98 earnings per share. The company's quarterly revenue was up 22.0% on a year-over-year basis. As a group, research analysts expect that Amgen Inc. will post 19.47 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Amgen（納斯達克股票代碼：AMGN - 獲取免費報告）於 5 月 2 日星期四發佈了其盈利結果。該醫療研究公司報告本季度每股盈利 3.96 美元，超過分析師對 3.76 美元的共識預期 0.20 美元。Amgen 的淨利潤率為 12.74%，淨資產收益率為 156.21%。本季度，該公司的營收為 74.5 億美元，略高於分析師對 74.5 億美元的預期。與去年同期相比，公司的季度營收增長了 22.0%。研究分析師預計，Amgen Inc.本財年的每股盈利將達到 19.47 美元。</p>
</div><h2>Amgen Company Profile (Free Report)</h2>
<div class="lb-trans"><h2>Amgen 公司簡介（免費報告）</h2>
</div><p>Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.</p>
<div class="lb-trans"><p>Amgen Inc（安進公司）在全球範圍內發現、開發、生產和提供人類治療藥物。該公司的主要產品包括用於治療斑塊性銀屑病、類風濕關節炎和銀屑病性關節炎的安達治（Enbrel）；用於治療成年患者斑塊性銀屑病、銀屑病性關節炎和貝赫切特氏病口腔潰瘍的奧特茲拉（Otezla）；用於治療絕經後婦女骨質疏鬆症的普羅利亞（Prolia）；用於預防骨相關事件的 XGEVA；降低心肌梗死、中風和冠狀動脈重建風險的瑞帕塔（Repatha）；用於治療免疫性血小板減少症患者的 Nplate；用於治療複發性或難治性多發性骨髓瘤患者的 KYPROLIS；用於治療紅細胞數量低於正常水平和貧血的阿拉內斯普（Aranesp）；用於治療絕經後男性和女性骨質疏鬆症的伊文尼蒂（EVENITY）；用於治療野生型 RAS 轉移性結直腸癌患者的維克替胞（Vectibix）；用於治療急性淋巴細胞白血病患者的布林西託（BLINCYTO）；用於治療甲狀腺眼病的泰珀扎（TEPEZZA）；以及用於治療慢性難治性痛風的克里斯特克薩（KRYSTEXXA）。</p>
</div><h2>Recommended Stories</h2>
<ul>
<li>Five stocks we like better than Amgen</li>
<li>How Can Investors Benefit From After-Hours Trading</li>
<li>What's Behind Walgreens Stock Plunge: What Investors Can Do Next</li>
<li>What is the Dogs of the Dow Strategy? Overview and Examples</li>
<li>MarketBeat Week in Review – 6/24 - 6/28</li>
<li>What is the S&amp;P 500 and How It is Distinct from Other Indexes</li>
<li>General Mills Stock Drops After Revenue Miss in Fiscal Q4 2024</li>
</ul>
<div class="lb-trans"><h2>推薦故事</h2>
<ul>
<li>五隻我們比安進更喜歡的股票</li>
<li>投資者如何從盤後交易中受益</li>
<li>瓦爾格林股價暴跌背後的原因：投資者下一步該怎麼做</li>
<li>道指狗策略背後的原理和示例</li>
<li>MarketBeat 周評 - 6/24 - 6/28</li>
<li>什麼是標普 500 指數及其與其他指數的區別</li>
<li>通用磨坊財報季度四營收不及預期後股價下跌</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1HTg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=AMGN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>這則即時新聞警報是由 Narrative Science 技術和 MarketBeat 的財務數據生成，旨在為讀者提供最快速和最準確的報道。本故事在發佈前經過 MarketBeat 編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><p>→ The Election SHOCK Nobody Expected… (But You’ll See it Coming) (From Banyan Hill Publishing)(Ad)</p>
<div class="lb-trans"><p>→ 意想不到的選舉震撼…（但你會看到它的到來）（來自 Banyan Hill Publishing）（廣告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NTk4" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=8598&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Amgen right now?</h2>
<div class="lb-trans"><h2>現在是否值得投資 1000 美元購買安進股票？</h2>
</div><p>Before you consider Amgen, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮購買安進股票之前，您應該聽聽這個消息。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amgen wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 追蹤華爾街評級最高、表現最佳的研究分析師以及他們每天向客户推薦的股票。MarketBeat 已經確定了五隻頂級分析師悄悄告訴他們的客户現在購買的股票清單…而安進並不在其中。</p>
</div><p>While Amgen currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然安進目前在分析師中有 “中等買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Sawyer & Company Inc 出售了 29,752 股安進公司（NASDAQ:AMGN）的股票